Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro

Ophthalmic Research

Volumn 39, Issue 6, 2007, Pages 302-307

  Wang, Chunfang ^a,c   Li, Bin ^a,e   Zhang, Haiyan ^b   Li, Weihong ^b   Jonas, Jost B ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e BEIJING INSTITUTE OF OPHTHALMOLOGY   (China)

Author keywords

Arsenic trioxide; Chemotherapy; Intraocular tumor; Uveal melanoma

Indexed keywords

ARSENIC TRIOXIDE; GLUTATHIONE PEROXIDASE;

APOPTOSIS; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSCOPY; PRIORITY JOURNAL; REVIEW; UVEA MELANOMA;

APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GLUTATHIONE PEROXIDASE; GROWTH INHIBITORS; HUMANS; MELANOMA; MEMBRANE POTENTIALS; MICROSCOPY, ELECTRON; MITOCHONDRIA; NECROSIS; OSMOLAR CONCENTRATION; OXIDES;

EID: 36949039410     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109985     Document Type: Review

References (16)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM: Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-251.
2. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD: Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98:383-389; discussion 390.
3. Woll E, Bedikian A, Legha SS: Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999;9:575-581.
4. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.
5. Wang ZY, Chen Z: Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol 2000;1:101-106.
6. Cheson BD, Zwiebel JA, Dancey J, Murgo A: Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000;27:560-577.
7. Liu LX, Zhu AL, Chen W, Guo HX, Wang XQ, Liu ZH, Zhang TD, Jiang HC, Wu M: The effect and mechanism of arsenic trioxide on hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 2005;43:33-36.
8. Mueller AJ, Freeman WR, Folberg R, Bartsch DU, Scheider A, Schaller U, Kampik A: Evaluation of microvascularization pattern visibility in human choroidal melanomas: comparison of confocal fluorescein with indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol 1999;237:448-456.
9. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE: Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 1989;30:829-834.
10. Wang CF, Li B, Zhang HY, Li WH, Sun YL, Xu YL: In vitro study on inhibition of human choroidal melanoma OCM-1 cell line by arsenic trioxide. Zhonghua Yan Ke Za Zhi 2005;41:887-891.
11. Schutte B, Nuydens R, Geerts H, Ramaekers F: Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods 1998;86:63-69.
12. Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, Dudek EJ: Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 1999;159:65-75.
13. Dai J, Weinberg RS, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277.
14. Zamzami N, Hirsch T, Dallaporta B, Petit PX, Kroemer G: Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. J Bioenerg Bio membr 1997;29:185-193.
15. Rosser BG, Gores GJ: Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 1995;108:252-275.
16. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005;104:1687-1692.